TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/26/2024
Back to search
Official data from USPTO
SYNENDOS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
SYNENDOS
ST13
US500000079330074Class
5, 42, 44
Filing
79330074
Registration
7141186
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
38
Latest update
02/26/2024
Trademark type
Word
Nice classes
5, 42, 44
Filing date
11/10/2021
Registration date
08/22/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/22/2023
Last transaction
02/26/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
25
Owner location
CH
Examiner
MANCA, ALBERTO I
Law office
L80
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Synendos Therapeutics AG
Representatives
Catherine F. Hoffman Baker, Donelson, Bearman, Caldwell, & Berkowitz, PC
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical products for the treatment of neuropsychiatricneurological and psychiatric diseases and disorders; pharmaceutical products for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalrenalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatricinflammatoryimmuneautoimmunegenetic diseases and disorders; medical preparations and substances for the treatment of neuropsychiatricneurological and psychiatric diseases and disorders; medical preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalrenalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatricinflammatoryimmuneautoimmunegenetic diseases and disorders; veterinary preparations and substances for the treatment of neuropsychiatricneurological and psychiatric diseases and disorders; veterinary preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalrenalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatricinflammatoryimmuneautoimmunegenetic diseases and disorders; sanitary preparations for medical use; medicines for pharmaceutical use for the treatment of neuropsychiatricneurological and psychiatric diseases and disorders; medicines for pharmaceutical use for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalrenalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatricinflammatoryimmuneautoimmunegenetic diseases and disorders; medicines for human medicine for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalrenalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatricinflammatoryimmuneautoimmunegenetic diseases and disorders; medicines for human medicinepharmaceutical preparations acting on the central nervous systembiopharmaceutical preparations acting on the central nervous systempharmaceutical agents affecting the peripheral nervous system and biopharmaceutical agents affecting the peripheral nervous system; medicines for human medicinemedicines for treating biochemical imbalances in vivo; chemical-pharmaceutical preparationspharmaceutical preparations acting on the central nervous systembiopharmaceutical preparations acting on the central nervous systempharmaceutical agents affecting the peripheral nervous system and biopharmaceutical agents affecting the peripheral nervous system; chemical preparations for medical usepharmaceutical preparations acting on the central nervous systembiopharmaceutical preparations acting on the central nervous systempharmaceutical agents affecting the peripheral nervous system and biopharmaceutical agents affecting the peripheral nervous system; chemical preparations for pharmaceutical usepharmaceutical preparations acting on the central nervous systembiopharmaceutical preparations acting on the central nervous systempharmaceutical agents affecting the peripheral nervous system and biopharmaceutical agents affecting the peripheral nervous system; chemical preparations for veterinary usepharmaceutical preparations acting on the central nervous systembiopharmaceutical preparations acting on the central nervous systempharmaceutical agents affecting the peripheral nervous system and biopharmaceutical agents affecting the peripheral nervous system; chemical preparations for medical use for treating biochemical imbalances in vivo; chemical preparations for veterinary use for treating biochemical imbalances in vivo; diagnostic substancespreparations and agents for medical use
Class 42
Scientific and technological servicesscientific researchanalysistesting in the fields of pharmaceuticalsbiopharmaceuticalschemistrybiologybiochemistry; industrial analysis servicesindustrial analysis in the fields of pharmaceuticalsbiopharmaceuticals; industrial research services in the fields of pharmaceuticalsbiopharmaceuticals; scientific research and development; scientific research; scientific analysisbiological analysisbiochemical analysischemical analysis; conducting chemical and biological analyses for scientific purposes; conducting medical analysis for scientific purposesbiological analysisbiochemical analysischemical analysisblood analysis; medical research; pharmaceutical research; research in the fields of chemistry and biology; biotechnological research services; providing medical and scientific research informationproviding information and data with respect to medical and veterinary research and development; providing information with respect to medical and scientific research in the field of pharmaceutical products; providing scientific information on research in the field of pharmaceutical products and biomedicine
Class 44
Medical services; veterinary services; hygienic care for human beings; medical and pharmaceutical consultancy services; medical tests for diagnostic or treatment purposes; conducting of medical examinations; consultations regarding pharmacology; pharmaceutical consultingconsultant and information services relating to pharmaceutical products; conducting of chemicalmedical and biological analyses for medical diagnosis being medical diagnostic testing services; consultancy and information services relating to medical products being pharmaceutical consultation services; medical analysis services relating to the treatment of patients; medical consultancy services; pharmacy advice being pharmaceutical consultation
Publications
History of USPTO decisions and trademark events.
38 publications found
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/26/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/26/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
02/26/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
02/26/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/11/2023
FICS
FINAL DISPOSITION NOTICE SENT TO IB
11/22/2023
FIMP
FINAL DISPOSITION PROCESSED
11/22/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
11/22/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/22/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
08/22/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
06/19/2023
GPNX
NOTIFICATION PROCESSED BY IB
06/06/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/06/2023
PUBO
PUBLISHED FOR OPPOSITION
06/06/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
05/31/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
05/31/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
05/17/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
05/17/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/17/2023
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
05/06/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/01/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
05/01/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
05/01/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
05/01/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
05/01/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/30/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/30/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/30/2023
RFNT
REFUSAL PROCESSED BY IB
10/25/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
10/01/2022
RFRR
REFUSAL PROCESSED BY MPU
10/01/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/25/2022
CNRT
NON-FINAL ACTION WRITTEN
08/24/2022
DOCK
ASSIGNED TO EXAMINER
08/22/2022
MAFR
APPLICATION FILING RECEIPT MAILED
01/08/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/04/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/30/2021
Continuous trademark protection
Get notified about every new filing that threatens SYNENDOS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.